MENX

Annales d'Endocrinologie

Volumn 73, Issue 2, 2012, Pages 65-70

  Pellegata, Natalia S ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P27;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CANCER CLASSIFICATION; CANCER SUSCEPTIBILITY; CDKN1B GENE; DISEASE ASSOCIATION; DISEASE MODEL; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC LINKAGE; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MEN1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; MULTIPLE ENDOCRINE NEOPLASIA TYPE 4; MULTIPLE ENDOCRINE NEOPLASIA X; NONHUMAN; PENETRANCE; PHENOTYPE; PROTEIN FUNCTION; RET GENE;

ADENOMA; ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; PHENOTYPE; PITUITARY NEOPLASMS; RATS;

EID: 84860915662     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.04.001     Document Type: Article

References (28)

1. Fritz A., Walch A., Piotrowska K., Rosemann M., Schäffer E., Weber K., et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 2002, 62:3048-3051.
2. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Höfler H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006, 103:15558-15563.
3. Piotrowska K., Pellegata N.S., Rosemann M., Fritz A., Graw J., Atkinson M.J. Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm Genome 2004, 15:135-141.
4. Marinoni I., Pellegata N.S. p27, a novel MEN gene?. Neuroendocrinology 2010, 93:19-28.
5. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685.
6. Kamura T., Hara T., Matsumoto M., Ishida N., Okumura F., Hatakeyama S., et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 2004, 6:1229-1235.
7. Besson A., Hwang H.C., Cicero S., Donovan S.L., Gurian-West M., Johnson D., et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007, 21:1731-1746.
8. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer, prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008, 8:253-267.
9. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997, 3:231-234.
10. Canavese G., Azzoni C., Pizzi S., Corleto V.D., Pasquali C., et al. p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol 2001, 32:1094-1101.
11. Erickson L.A., Jin L., Wollan P., Thompson G.B., van Heerden J.A., et al. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol 1999, 23:288-295.
12. Pellegata N.S., Quintanilla-Martinez L., Keller G., Liyanarachchi S., Höfler H., et al. Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutations and rarely with deletions. Virchows Arch 2007, 451:37-46.
13. Lidhar K., Korbonits M., Jordan S., Khalimova Z., Kaltsas G., Lu X., et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999, 84:3823-3830.
14. Molatore S., Kiermaier E., Jung C.B., Pulz E., Höfler H., Atkinson M.J., et al. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol Cancer 2010, 9:116.
15. Marinoni I, Lee M, Mountford S, Perren A, Bravi I, Jennen L, et al. Characterization of MENX-associated pituitary tumors. Neuropath App Neurobiol 2012, in press.
16. Ferrante E., Ferraroni M., Castrignano T., Menicatti L., Anagni M., et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 2006, 155:823-829.
17. Wass J.A., Karavitaki N. Nonfunctioning pituitary adenomas: the Oxford experience. Nat Rev Endocrinol 2009, 5:519-522.
18. Greenman Y., Tordjman K., Osher E., Veshchev I., Shenkerman G., et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf) 2005, 63:39-44.
19. Colao A., Filippella M., Pivonello R., Di Somma C., Faggiano A., et al. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol 2007, 156(Suppl. 1):S57-S63.
20. Musat M., Korbonits M., Kola B., Borboli N., Hanson M.R., et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005, 12:423-433.
21. Zatelli M.C., Minoia M., Filieri C., Tagliati F., Buratto M., et al. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2010, 95:968-976.
22. Gorshtein A., Rubinfeld H., Kendler E., Theodoropoulou M., Cerovac V., et al. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 2009, 16:1017-1027.
23. Cerovac V., Monteserin-Garcia J., Rubinfeld H., Buchfelder M., Losa M., et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010, 70:666-674.
24. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
25. Lee M., Theodoropoulou M., Graw J., Roncaroli F., Zatelli M.C., et al. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol Cancer Ther 2011, 10:1450-1459.
26. Cerovac V., Tichomirowa M., Stalla G., Theodoropoulou M. The dual PI3K/mTOR inhibitor NVP-BEZ235 has a potent antiproliferative action in human nonfunctioning pituitary adenomas. Endocr Abstr 2011, 26:P295.
27. Lidhar K., Korbonits M., Jordan S., Khalimova Z., Kaltsas G., et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999, 84:3823-3830.
28. Korbonits M., Chahal H.S., Kaltsas G., Jordan S., Urmanova Y., et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002, 87:2635-2643.